000064480 001__ 64480
000064480 005__ 20201105083207.0
000064480 0247_ $$2doi$$a10.1093/infdis/jix030
000064480 0248_ $$2sideral$$a101976
000064480 037__ $$aART-2017-101976
000064480 041__ $$aeng
000064480 100__ $$aClark, S.
000064480 245__ $$aRevaccination of Guinea pigs with the live attenuated Mycobacterium tuberculosis vaccine MTBVAC improves BCG's protection against tuberculosis
000064480 260__ $$c2017
000064480 5060_ $$aAccess copy available to the general public$$fUnrestricted
000064480 5203_ $$aBackground: The need for an effective vaccine against human tuberculosis has driven the development of different candidates and vaccination strategies. Novel live attenuated vaccines are being developed that promise greater safety and efficacy than BCG against tuberculosis. We combined BCG with the vaccine MTBVAC to evaluate whether the efficacy of either vaccine would be affected upon revaccination. Methods: In a well-established Guinea pig model of aerosol infection with Mycobacterium tuberculosis, BCG and MTBVAC delivered via various prime-boost combinations or alone were compared. Efficacy was determined by a reduction in bacterial load 4 weeks after challenge. Results: Efficacy data suggests MTBVAC-associated immunity is longer lasting than that of BCG when given as a single dose. Long and short intervals between BCG prime and MTBVAC boost resulted in improved efficacy in lungs, compared with BCG given alone. A shorter interval between MTBVAC prime and BCG boost resulted in improved efficacy in lungs, compared with BCG given alone. A longer interval resulted in protection equivalent to that of BCG given alone. Conclusions: These data indicate that, rather than boosting the waning efficacy of BCG, a vaccination schedule involving a combination of the 2 vaccines yielded stronger immunity to M. tuberculosis infection. This work supports development of MTBVAC use as a revaccination strategy to improve on the effects of BCG in vaccinated people living in tuberculosis-endemic countries.
000064480 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000064480 590__ $$a5.186$$b2017
000064480 591__ $$aIMMUNOLOGY$$b35 / 155 = 0.226$$c2017$$dQ1$$eT1
000064480 591__ $$aMICROBIOLOGY$$b20 / 125 = 0.16$$c2017$$dQ1$$eT1
000064480 591__ $$aINFECTIOUS DISEASES$$b9 / 88 = 0.102$$c2017$$dQ1$$eT1
000064480 592__ $$a3.302$$b2017
000064480 593__ $$aInfectious Diseases$$c2017$$dQ1
000064480 593__ $$aImmunology and Allergy$$c2017$$dQ1
000064480 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000064480 700__ $$aLanni, F.
000064480 700__ $$0(orcid)0000-0001-8644-120X$$aMarinova, D.$$uUniversidad de Zaragoza
000064480 700__ $$aRayner, E.
000064480 700__ $$0(orcid)0000-0003-2993-5478$$aMartin, C.$$uUniversidad de Zaragoza
000064480 700__ $$aWilliams, A.
000064480 7102_ $$11008$$2630$$aUniversidad de Zaragoza$$bDpto. Microb.Med.Pr.,Sal.Públ.$$cÁrea Microbiología
000064480 7102_ $$11008$$2X$$aUniversidad de Zaragoza$$bDpto. Microb.Med.Pr.,Sal.Públ.$$cProy. investigación HQA
000064480 773__ $$g216, 5 (2017), 525-533$$pJ. infect. dis.$$tJOURNAL OF INFECTIOUS DISEASES$$x0022-1899
000064480 8564_ $$s2260886$$uhttps://zaguan.unizar.es/record/64480/files/texto_completo.pdf$$yPostprint
000064480 8564_ $$s50535$$uhttps://zaguan.unizar.es/record/64480/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000064480 909CO $$ooai:zaguan.unizar.es:64480$$particulos$$pdriver
000064480 951__ $$a2020-11-05-08:19:15
000064480 980__ $$aARTICLE